I'd like to remind everyone, and any new investors who may
I'd like to remind everyone, and any new investors who may be reading and not posting, that Leo has stated many times over the years that CTIX was not looking to partner or sell their drugs until they felt that they have maximized the value of them. I am sure it is highly likely that CTIX could partner or sell just about any of the drugs right now, as-is, but they will not receive as good a price for them as they will with the later stage trial data. Plus as the drugs succeed in later trials risk is reduced, and reduced risk for BP is worth lots of additional money. Leo is a shareholder and Menon is a shareholder; if they are confident that the drugs are working well, and that they have enough funding to continue pursuing trials for the next year, what motivation do they have to diminish value just for the sake of partnership in the short term?
I am fully aware that CTIX does not currently have the funding to get any of the drugs through a phase 3 and to market, but they have sufficient funds for a year to continue trials and increase the value of the drugs for the future partnership/sale. Plus, if the plan doesn't work to get a better deal in the future, and management has been choosing to pass on less than stellar deals, then that tells me the worst case scenario backup plan is that they will partner or sell a drug for less money in order to keep solvent. It would not be ideal to have to do that, but I think that is a worthwhile gamble for the potential of stellar returns upon future trial success.
So that is why I do not put any weight to the continued statements that CTIX can't find a partner, or is somehow screwed and going to go bankrupt. They are choosing to continue down this short term path (which I admit is painful as a shareholder to see paper losses) in order to create a better long term gain for all of us.
6
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...
Continue Reading
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...
Continue Reading
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...
Continue Reading
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
News Articles
